A Study on the efficacy of neoadjuvant chemotherapy with carboplatin, docetaxel and bevacizumab in patients with non-squamous non-small cell lung cancer

A Study on the efficacy of neoadjuvant chemotherapy with carboplatin, docetaxel and bevacizumab in patients with non-squamous non-small cell lung cancer - A Study on the efficacy of neoadjuvant chemotherapy with carboplatin, docetaxel and bevacizumab in patients with non-squamous non-small cell lung cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008817

Enrollment

Registered

2012-09-01

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

Carboplatin + Docetaxel + Bevacizumab day1 q3w 2cycles Surgical operation is performed over 5 weeks after protocol therapy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologically or pathologically confirmed non-squamous non-small cell lung cancer 2) Clinical stage IB- IIIA 3) Age:20-74years old 4) ECOG PS 0-1 5) Patients without previous treatment for lung cancer 6) If the patient underwent therapy, there should be the following interval between the therapy and the registration -Open biopsy,Treatment of injury->2 weeks -Aspiration biopsy,->1 week 7) Sufficient organ function 8) Written IC

Exclusion criteria

Exclusion criteria: 1) History of severe drug allergy 2) Patients with uncontrollable complications 3) Patients with symptomatic Brain metastasis 4) History of hemoptysis ( >= 2.5mL) 5) History of continuous hemosputum 6) Patients with massive pleural and cardiac effusion 7) Patients with uncontrollable peptic ulcer 8) History of myocardial infarction or cerebral infarction 9) Current or previous history of GI perforation 10) Patients with therapeutic anticoagulopathy 11) Pregnancy, breast feeding and suspected pregnancy 12) Active concomitant malignancy 13) Inappropriate patients for this study judged by the physicians

Design outcomes

Primary

Measure	Time frame
Pathological complete resection rate	—

Secondary

Measure	Time frame
Pathological response rate (pRR) Complete resection rate Relapse-free survival (RFS) Overall survival (OS) Safety	—

Countries

Japan

Contacts

Public ContactMotohiko Furuichi

Nihon University School of Medicine Itabashi Hospital Department of respiratory surgery

furuichi.motohiko@nihon-u.ac.jp03-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026